The BMS-Pfizer Alliance lawsuit wins!

The Bristol-Myers Squibb (BMS)-Pfizer Alliance recently issued a statement that the U.

According to the CAFC's ruling, the earliest time for a generic drug manufacturer to be allowed to launch its apixaban generic drug product is April 1, 2028, but this may depend on additional litigation and challenges

Eliquis is an oral anticoagulant discovered by BMS

Eliquis was approved for listing in the European Union and the United States in May 2011 and December 2012, respectively, and entered the Chinese market in January 2013

In the more than ten years since its launch, Eliquis has grown into a star product of BMS and Pfizer

Over the years, BMS and Pfizer have also been working hard to fight against generic drug manufacturers

BMS and Pfizer eventually reached a legal settlement with several of their competitors, including Mylan (now Huizhi) and Micro Labs.

The CAFC ruling is a good thing for the BMS-Pfizer alliance

Reference source:

1.